How does EGFR mutation cause cancer?

How does EGFR mutation cause cancer?

In the case of EGFR-positive non small cell lung cancer (NSCLC), a mutation, or damage, in the EGFR gene causes the EGFR protein to remain stuck in the “on” position. This “drives” abnormal cell growth, which is what cancer is. EGFR is important in many cancers, including lung cancer.

What happens when EGFR is mutated?

EGFR (epidermal growth factor receptor) is a protein on cells that helps them grow. A mutation in the gene for EGFR can make it grow too much, which can cause cancer.

How common is EGFR in NSCLC?

EGFR mutations in NSCLC cells were first discovered in 2004 [2, 3]. The majority of EGFR mutations in NSCLC occurs in exons 18– 21 of the tyrosine kinase domain of the receptor. EGFR mutations occur in 40%–60% of South-East Asian patients or 10%–20% of Caucasian patients with lung adenocarcinomas [4–6].

How are mutations in epidermal growth factor receptor linked to lung cancer?

Abstract. Mutations in epidermal growth factor receptor have been discovered in association with some lung cancers. Lung adenocarcinomas with mutated epidermal growth factor receptor have significant responses to tyrosine kinase inhibitors, although for unselected patients it does not appear to have a survival benefit.

How are EGFR mutations used to treat lung cancer?

Epidermal growth factor receptor mutations in lung cancer The development and clinical application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.

What kind of mutations are found in lung cancer?

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Are there any epidermal growth factor receptor mutations that are targetable?

However, recent studies revealed that these rare genotypes could be targetable if appropriate TKI are selected. For example, G719X (X denotes A, S, C and so on), Del18, E709K, insertions in exon 19 (Ins19), S768I or L861Q showed moderate sensitivities to gefitinib or erlotinb with ORR of 30%-50%.